Allarity Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Allarity Therapeutics, Inc. (ALLR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $559.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-08.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2024-03-08
- Allarity Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $559.00K, a 25.86% decline from fiscal 2022.
- Allarity Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $754.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2023-12-31 | $559.00K 10-K · filed 2024-03-08 |
| 2022-12-31 | $754.00K 10-K · filed 2024-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |